How much longer does Keytruda extend life?
Keytruda (pembrolizumab) can extend survival, but the length of benefit depends on the cancer type, disease stage, and whether it’s used as first-line or after prior treatment. Without the specific study (and cancer indication) it’s impossible to state one universal “how long.”
What affects the survival benefit (and why the answer changes)?
Clinical trial results for Keytruda vary widely because:
- Different cancers have different baseline prognoses.
- Keytruda is sometimes given in earlier lines of therapy and sometimes after the cancer has progressed.
- Trials measure different endpoints (overall survival vs. progression-free survival), which can be confused when people ask about “how long” it helps.
What patients usually mean by “extend life”
People often mean one of these:
- Overall survival: how long patients live compared with a control arm.
- Long-term survival: the share of patients alive at a specific time point (for example, years after starting treatment).
- Durability of response: how long tumors stay controlled once Keytruda works.
Can you get a specific number?
If you tell me which cancer Keytruda is being used for (for example, lung cancer, melanoma, head and neck cancer, bladder cancer, etc.) and the setting (first-line vs. after chemotherapy, metastatic vs. early stage), I can summarize what the reported overall survival results show for that situation.
Source